US · Healthcare · Biotechnology
EPS came in at -0.18 against a street estimate of -0.17 — a miss of 5.9%.
Analysts rate Immix Biopharma Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $24.30.
| Fund | Stake |
|---|---|
| Jupiter Topco LLC | 11.80% |
| HHG PLC | 5.79% |
| Saturn V Capital Management LLC | 5.62% |
| Eventide Asset Management, LLC | 4.69% |
| State Street Corp | 3.62% |
| BlackRock Inc | 3.61% |
| Deep Track Capital, LP | 3.35% |
| Vanguard Capital Management, LLC | 3.02% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 HEADLINE NUMBERS • Immix Biopharma agreed to sell 11,363,637 shares of common stock at $11.00 per share in an underwritten public offering. • Expect | 2026-09-30 |
| Reg FD disclosure · Q3 2026 HEADLINE NUMBERS • Immix Biopharma announced an 89% complete response rate: 40 of 45 patients in the Phase 2 NEXICART-2 trial achieved complete respo | 2026-09-29 |
| Quarterly report · Q2 2026 IMMIX BIOPHARMA, INC. – FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $225.5 million as of June 30, 2026 (up from $93.9 million at D | 2026-08-07 |
| Company announcement · Q3 2026 IMMIX BIOPHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics disclosed in this filing • Document is a current report (Form 8-K) d | 2026-07-20 |
| Shareholder vote results · Q2 2026 IMMIX BIOPHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 22, 2026 • Total votes cast: approximately 42.3 million shares ( | 2026-05-29 |
| Company announcement · Q2 2026 IMMIX BIOPHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Stock offering size: 16,778,524 shares of common stock • Public offering price: $8.94 pe | 2026-05-21 |
| Reg FD disclosure · Q2 2026 IMMIX BIOPHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Complete Response Rate: 95% (19 of 20 patients in NEXICART-2 Phase 2 trial achieved comp | 2026-05-21 |
| Quarterly report · Q1 2026 IMMIX BIOPHARMA, INC. – Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $79.3 million in cash and cash equivalents as of March 31, 2026 | 2026-05-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immix Biopharma Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.